{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:58:56Z","timestamp":1740135536306,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:00:00Z","timestamp":1654300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:00:00Z","timestamp":1654300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The current study aimed to reveal the correlation of beta-cell function and insulin sensitivity with glycemic control and weight control before and after medical nutrition therapy (MNT) in patients with newly-diagnosed type 2 diabetes mellitus.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively analyzed consecutive 68 patients with newly-diagnosed type 2 diabetes mellitus who started MNT without antihyperglycemic medications and underwent a 75-g oral glucose tolerance test (OGTT) before and after the therapy. Beta-cell function was evaluated by the OGTT-derived disposition index, whereas insulin sensitivity was evaluated by Matsuda\u2019s insulin sensitivity index.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After 4.0\u2009\u00b1\u20091.5\u00a0months of MNT, mean HbA1c and body mass index significantly decreased from 9.6\u2009\u00b1\u20091.8% to 7.2\u2009\u00b1\u20091.0% and from 26.9\u2009\u00b1\u20094.1 to 25.4\u2009\u00b1\u20093.7\u00a0kg\/m<jats:sup>2<\/jats:sup> (both <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), while the median disposition index and Matsuda\u2019s index significantly increased from 0.34 (0.20\u20130.68) to 0.88 (0.53\u20131.52) (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and from 4.70 (2.95\u20135.93) to 5.17 (3.48\u20136.89) (<jats:italic>P<\/jats:italic>\u2009=\u20090.003), respectively. The disposition index was significantly correlated with HbA1c levels both before and after MNT (<jats:italic>r<\/jats:italic>\u2009=\u2009-0.61 and -0.68; both <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). The magnitude of the correlation after MNT was not different from that before MNT (<jats:italic>P<\/jats:italic>\u2009=\u20090.42). Matsuda\u2019s index was correlated not with HbA1c levels but with body mass index, both before (<jats:italic>r<\/jats:italic>\u2009=\u20090.07 [<jats:italic>P<\/jats:italic>\u2009=\u20090.57] and <jats:italic>r<\/jats:italic>\u2009=\u2009-0.58 [<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001]) and after MNT (<jats:italic>r<\/jats:italic>\u2009=\u2009-0.01 [<jats:italic>P<\/jats:italic>\u2009=\u20090.95] and <jats:italic>r<\/jats:italic>\u2009=\u2009-0.52 [<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001]).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Beta-cell function was improved in conjunction with glycemic control after MNT in patients with newly-diagnosed type 2 diabetes mellitus. Insulin sensitivity was linked with weight control rather than glycemic control.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-022-01064-w","type":"journal-article","created":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T15:02:42Z","timestamp":1654354962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Improvement of beta-cell function in conjunction with glycemic control after medical nutrition therapy in newly-diagnosed type 2 diabetes mellitus"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5105-041X","authenticated-orcid":false,"given":"Mitsuyoshi","family":"Takahara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Shiraiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Maeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Shiraiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Katakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iichiro","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,4]]},"reference":[{"key":"1064_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1177\/0115426504019002137","volume":"19","author":"MJ Franz","year":"2004","unstructured":"Franz MJ. Evidence-based medical nutrition therapy for diabetes. Nutr Clin Pract. 2004;19:137\u201344.","journal-title":"Nutr Clin Pract"},{"key":"1064_CR2","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2337\/diab.44.11.1249","volume":"44","author":"UK Prospective Diabetes Study Group","year":"1995","unstructured":"UK Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years\u2019 therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249\u201358.","journal-title":"Diabetes"},{"key":"1064_CR3","doi-asserted-by":"publisher","first-page":"442","DOI":"10.2337\/diacare.15.3.442","volume":"15","author":"JL Leahy","year":"1992","unstructured":"Leahy JL, Bonner-Weir S, Weir GC. Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care. 1992;15:442\u201355.","journal-title":"Diabetes Care"},{"key":"1064_CR4","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.2337\/dc17-S011","volume":"40","author":"American Diabetes A","year":"2017","unstructured":"American Diabetes A. 8. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2017;40:S64\u201374.","journal-title":"Diabetes Care"},{"key":"1064_CR5","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1507\/endocrj.EJ17-0222","volume":"64","author":"M Takahara","year":"2017","unstructured":"Takahara M, Shiraiwa T, Katakami N, Matsuoka TA, Shimomura I. Marked recovery from glucotoxicity of beta-cell function after medical nutrition therapy without pharmacotherapy in type 2 diabetic outpatients with extreme hyperglycemia: a pilot retrospective study. Endocr J. 2017;64:1125\u20139.","journal-title":"Endocr J"},{"key":"1064_CR6","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","volume":"22","author":"M Matsuda","year":"1999","unstructured":"Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462\u201370.","journal-title":"Diabetes Care"},{"key":"1064_CR7","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","volume":"364","author":"RA DeFronzo","year":"2011","unstructured":"DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104\u201315.","journal-title":"N Engl J Med"},{"key":"1064_CR8","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.2337\/db05-1200","volume":"55","author":"MA Abdul-Ghani","year":"2006","unstructured":"Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes. 2006;55:1430\u20135.","journal-title":"Diabetes"},{"key":"1064_CR9","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.2337\/dc13-0520","volume":"36","author":"RA Defronzo","year":"2013","unstructured":"Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al. Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care. 2013;36:3607\u201312.","journal-title":"Diabetes Care"},{"key":"1064_CR10","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412\u20139.","journal-title":"Diabetologia"},{"key":"1064_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1046\/j.1464-5491.2002.00661.x","volume":"19","author":"CJ Ostgren","year":"2002","unstructured":"Ostgren CJ, Lindblad U, Ranstam J, Melander A, Rastam L, Skaraborg h, et al. Glycaemic control, disease duration and beta-cell function in patients with Type 2 diabetes in a Swedish community. Skaraborg Hypertension and Diabetes Project. Diabet Med. 2002;19:125\u20139.","journal-title":"Diabet Med."},{"key":"1064_CR12","first-page":"198","volume":"87","author":"AI Albarrak","year":"2002","unstructured":"Albarrak AI, Luzio SD, Chassin LJ, Playle RA, Owens DR, Hovorka R. Associations of glucose control with insulin sensitivity and pancreatic beta-cell responsiveness in newly presenting type 2 diabetes. J Clin Endocrinol Metab. 2002;87:198\u2013203.","journal-title":"J Clin Endocrinol Metab"},{"key":"1064_CR13","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/(SICI)1096-9136(199804)15:4<290::AID-DIA570>3.0.CO;2-M","volume":"15","author":"J Levy","year":"1998","unstructured":"Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med. 1998;15:290\u20136.","journal-title":"Diabet Med"},{"key":"1064_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ecl.2012.03.004","volume":"41","author":"JL Leahy","year":"2012","unstructured":"Leahy JL. Insulin therapy in type 2 diabetes mellitus. Endocrinol Metab Clin North Am. 2012;41:119\u201344.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1064_CR15","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1136\/bmj.39022.462546.80","volume":"333","author":"RJ Heine","year":"2006","unstructured":"Heine RJ, Diamant M, Mbanya JC, Nathan DM. Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure? BMJ. 2006;333:1200\u20134.","journal-title":"BMJ"},{"key":"1064_CR16","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1172\/JCI113157","volume":"80","author":"L Rossetti","year":"1987","unstructured":"Rossetti L, Shulman GI, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest. 1987;80:1037\u201344.","journal-title":"J Clin Invest"},{"key":"1064_CR17","doi-asserted-by":"publisher","first-page":"923","DOI":"10.3390\/jcm3030923","volume":"3","author":"Y Saisho","year":"2014","unstructured":"Saisho Y. Importance of beta cell function for the treatment of Type 2 diabetes. J Clin Med. 2014;3:923\u201343.","journal-title":"J Clin Med"},{"key":"1064_CR18","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.metabol.2013.05.022","volume":"62","author":"Y Okuno","year":"2013","unstructured":"Okuno Y, Komada H, Sakaguchi K, Nakamura T, Hashimoto N, Hirota Y, et al. Postprandial serum C-peptide to plasma glucose concentration ratio correlates with oral glucose tolerance test- and glucose clamp-based disposition indexes. Metabolism. 2013;62:1470\u20136.","journal-title":"Metabolism"},{"key":"1064_CR19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s00125-014-3414-6","volume":"58","author":"V Ahuja","year":"2015","unstructured":"Ahuja V, Kadowaki T, Evans RW, Kadota A, Okamura T, El Khoudary SR, et al. Comparison of HOMA-IR, HOMA-beta% and disposition index between US white men and Japanese men in Japan: the ERA JUMP study. Diabetologia. 2015;58:265\u201371.","journal-title":"Diabetologia"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01064-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-022-01064-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01064-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T15:04:33Z","timestamp":1654355073000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-022-01064-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,4]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1064"],"URL":"https:\/\/doi.org\/10.1186\/s12902-022-01064-w","relation":{},"ISSN":["1472-6823"],"issn-type":[{"type":"electronic","value":"1472-6823"}],"subject":[],"published":{"date-parts":[[2022,6,4]]},"assertion":[{"value":"4 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committees of Shiraiwa Medical Clinic (approval number, 2020902; approval date, September 2, 2020) and that of Osaka University Hospital (approval number 15395\u20133; approval date, September 7, 2020). Informed consent was exempted and instead relevant information regarding the study was open to the public, according to the Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan. The requirement for informed consent was waived by the Ethics Committee of Shiraiwa Medical Clinic and that of Osaka University Hospital, because of the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}